Journal: International journal of molecular sciences

Article Title: Preconditioned Chorionic Villus Mesenchymal Stem/Stromal Cells (CVMSCs) Minimize the Invasive Phenotypes of Breast Cancer Cell Line MDA231 In Vitro.

doi: 10.3390/ijms24119569

Figure Lengend Snippet: Figure 6. Modulation in expression of tumor suppressor proteins and oncogenes in MDA231 cells treated with preconditioned CVMSCs: flow cytometry analysis for the expression of tumor suppressor proteins modulated in MDA231 cells after treatment with preconditioned CVMSCs showed significant increase in the expression levels for CDH1 and IFN-gamma in both IC and CM settings as compared to untreated control (A(i)). Expression levels of oncogenes such as IDO, IL6, MMP7, and TGF-β1 reduced significantly in MDA231 cells in both IC and SF setting as compared to untreated control (B(i)). Data obtained by FACS analysis from three independent experiments were quantified and are shown in bar graphs as Mean Florescence Index (MFI) pertaining to CDH1 and IFN-gamma (A(ii)), and IDO, IL6, MMP7, and TGF-β1 (B(ii)), respectively. Bars represent standard errors. * p < 0.05.

Article Snippet: Fluorescent-labeled antibodies for flow cytometry experiments, including IFN-γ (Human IFN-gamma PE-conjugated Antibody) cat# IC285P; CDH1 (Human E-Cadherin PE-conjugated Antibody) cat# FAB18381P; IDO (Human Indoleamine 2,3-dioxygenase/IDO PE-conjugated Antibody) cat# IC6030P; IL6 (Human IL-6 PE-conjugated Antibody)cat# IC206P; MMP7 (Human MMP-7 PE-conjugated Antibody) cat# IC9071P; and TGF-β1 (Human TGF-beta 1 Alexa Fluor® 488-conjugated Antibody) cat# IC10502G were purchased from R&D Systems (Minneapolis, MN, USA).

Techniques: Expressing, Cytometry, Control

Journal: Molecular imaging

Article Title: Tryptophan PET Imaging of the Kynurenine Pathway in Patient-Derived Xenograft Models of Glioblastoma

doi: 10.1177/1536012116644881

Figure Lengend Snippet: Immunostaining for kynurenine pathway’s (KP) elements in patient and xenograft tumor tissues. Immunohistochemical staining for secondary antibody only control; the rate-limiting enzymes indoleamine 2,3-dioxygenase (IDO) 1, IDO2, and tryptophan 2,3-dioxygenase (TDO2); downstream enzymes kynureninase (KYNU) and kynurenine 3-monooxygenase (KMO); and l -type amino acid transporter 1 (LAT1), the membrane transporter that mediates the uptake of TRP and AMT. Left column: 13-058 patient tumor tissue and right column: mouse xenograft tumor tissue. Staining patterns are parallel between the 2 tumors with stronger signals found from IDO2 and TDO2 and the weakest signals found from IDO1 and KMO. The length of the scale bar is 100 µm. Insets: 4× greater magnification than the larger image.

Article Snippet: Primary antibodies used targeted the following proteins: IDO1 (0.1 mg/mL; cat.#NBP1-87702; Novus Biologicals, Littleton, Colorado), IDO2 (0.5 mg/mL; cat.#OAAB08672; Aviva Systems Biology, San Diego, California), TDO2 (0.3 mg/mL; cat# NBP2-13424; Novus Biologicals), KYNU (0.05 mg/mL; cat.#NBP1-56545; Novus Biologicals), KMO (concentration not provided by manufacturer; cat.#10698-1-AP; Proteintech, Chicago, Illinois), AHR (0.73 mg/mL; cat.#ab153744; Abcam, Cambridge, Massachusetts), and l -type amino acid transporter 1 (LAT1; 0.5 mg/mL; cat.#ab85226; Abcam).

Techniques: Immunostaining, Immunohistochemical staining, Staining, Control, Membrane

Journal: Cells

Article Title: Interferon-Gamma Primed Human Clonal Mesenchymal Stromal Cell Sheets Exhibit Enhanced Immunosuppressive Function

doi: 10.3390/cells11233738

Figure Lengend Snippet: Duration of IFN-γ priming is directly related to enhanced hcBMSC sheet gene expression of immunomodulatory factors. Quantitative real-time PCR gene expression for immunomodulatory genes ( a ) human leukocyte antigen DR (HLA-DRA), ( b ) programmed death ligand-1 (PD-L1), ( c ) indoleamine 2,3-dioxygenase (IDO-1), ( d ) interleukin 10 (IL-10), and ( e ) prostaglandin E synthase 2 (PTGES2). All gene expression is normalized to GAPDH, fold change is relative to non-primed control hBMSC sheet sample. Error bars represent means ± SE ( n = 6) (n.s. p ≥ 0.05, ** p < 0.01, *** p < 0.001) Statistical analysis p values are compared to non-IFN-γ hcBMSC sheets (non-IFN-γ, control).

Article Snippet: The concentration of soluble IL-10, IDO, PGE2, and PD-L1 per sample was quantified using human IL-10 DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA), human indoleamine 2,3-dioxygenase/IDO DuoSet ELISA kit (R&D Systems, Minneapolis, MN, USA), prostaglandin E2 Parameter Assay Kit (R&D Systems, Minneapolis, MN, USA), and human PD-L1 DuoSet ELISA Kit (R&D Systems, Minneapolis, MN, USA), respectively.

Techniques: Gene Expression, Real-time Polymerase Chain Reaction, Control

Journal: Molecular Cell

Article Title: Immune-regulated IDO1-dependent tryptophan metabolism is source of one-carbon units for pancreatic cancer and stellate cells

doi: 10.1016/j.molcel.2021.03.019

Figure Lengend Snippet:

Article Snippet: Rabbit monoclonal anti-IDO1 [mouse] (D8W5E) , CST , Cat#51851.

Techniques: Recombinant, Staining, Western Blot, Expressing, Plasmid Preparation, Cloning, RNAscope, Positive Control, Software

Journal: Cancer Medicine

Article Title: Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma

doi: 10.1002/cam4.6778

Figure Lengend Snippet: Clinicopathological data of patients with ovarian clear cell carcinoma ( n = 127).

Article Snippet: The sections were incubated in TRIS‐EDTA retrieval solution (10 mM Tris, 1 mM EDTA pH 9.0) or citric acid buffer (10 mM, pH 6.0) at 98°C for 20 min. Then, they were subsequently incubated for 20 min with primary antibodies, followed by incubation with anti‐rabbit immuno‐peroxidase polymer (Envision FLEX/HRP) for 20 min. Primary antibodies included antibodies against IDO1 (EPR20374, Abcam, ab211017, dilution 1:4000), IDO2 (8322548, Proteintech, 25053‐1‐AP, dilution 1:100), TDO2 (4071714, Proteintech, 15880‐1‐AP, dilution 1:100) and IL4I1 (EPR22070, Abcam, ab222102, dilution 1:2000).

Techniques:

Journal: Cancer Medicine

Article Title: Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma

doi: 10.1002/cam4.6778

Figure Lengend Snippet: Relations between expression of different Trp catabolising enzymes.

Article Snippet: The sections were incubated in TRIS‐EDTA retrieval solution (10 mM Tris, 1 mM EDTA pH 9.0) or citric acid buffer (10 mM, pH 6.0) at 98°C for 20 min. Then, they were subsequently incubated for 20 min with primary antibodies, followed by incubation with anti‐rabbit immuno‐peroxidase polymer (Envision FLEX/HRP) for 20 min. Primary antibodies included antibodies against IDO1 (EPR20374, Abcam, ab211017, dilution 1:4000), IDO2 (8322548, Proteintech, 25053‐1‐AP, dilution 1:100), TDO2 (4071714, Proteintech, 15880‐1‐AP, dilution 1:100) and IL4I1 (EPR22070, Abcam, ab222102, dilution 1:2000).

Techniques: Expressing

Journal: Cancer Medicine

Article Title: Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma

doi: 10.1002/cam4.6778

Figure Lengend Snippet: Relations between expression of Trp catabolising enzymes and clinical information.

Article Snippet: The sections were incubated in TRIS‐EDTA retrieval solution (10 mM Tris, 1 mM EDTA pH 9.0) or citric acid buffer (10 mM, pH 6.0) at 98°C for 20 min. Then, they were subsequently incubated for 20 min with primary antibodies, followed by incubation with anti‐rabbit immuno‐peroxidase polymer (Envision FLEX/HRP) for 20 min. Primary antibodies included antibodies against IDO1 (EPR20374, Abcam, ab211017, dilution 1:4000), IDO2 (8322548, Proteintech, 25053‐1‐AP, dilution 1:100), TDO2 (4071714, Proteintech, 15880‐1‐AP, dilution 1:100) and IL4I1 (EPR22070, Abcam, ab222102, dilution 1:2000).

Techniques: Expressing

Journal: Cancer Medicine

Article Title: Tryptophan metabolism enzymes are potential targets in ovarian clear cell carcinoma

doi: 10.1002/cam4.6778

Figure Lengend Snippet: Prognostic value of clinicopathological parameters in OCCC (PFS, n = 96). ^a

Article Snippet: The sections were incubated in TRIS‐EDTA retrieval solution (10 mM Tris, 1 mM EDTA pH 9.0) or citric acid buffer (10 mM, pH 6.0) at 98°C for 20 min. Then, they were subsequently incubated for 20 min with primary antibodies, followed by incubation with anti‐rabbit immuno‐peroxidase polymer (Envision FLEX/HRP) for 20 min. Primary antibodies included antibodies against IDO1 (EPR20374, Abcam, ab211017, dilution 1:4000), IDO2 (8322548, Proteintech, 25053‐1‐AP, dilution 1:100), TDO2 (4071714, Proteintech, 15880‐1‐AP, dilution 1:100) and IL4I1 (EPR22070, Abcam, ab222102, dilution 1:2000).

Techniques: